Cost-justification of a clinical pharmacist-managed anticoagulation clinic.
A cost-benefit evaluation of a clinical pharmacist-managed anticoagulation clinic (AC) was performed. Outpatient and hospital records were examined for 26 patients in the treatment group with an AC clinic and 26 patients in the control group. Therapeutic prothrombin times were maintained within the treatment group to a significantly greater extent than within the control group (p less than 0.001). The AC was successful in preventing hospitalizations resulting from hemorrhage or thromboembolism (p less than 0.01). The abnormal prothrombin times on admission in the control group correlated with hemorrhagic and thromboembolic admissions (p less than 0.05, p less than 0.005, respectively). Patients were hospitalized 3.22 days and .048 days per patient-treatment-year in the control and treatment groups, respectively. The net savings in reduced hospitalization costs per year in the treatment group was $211776. The benefit:cost ratio (B:C) was 6.55, suggesting the program is socially valuable. This clinical pharmacist-managed AC was effective in maintaining therapeutic prothrombin times, and reducing the incidence of hospitalization resulting from anticoagulation complications, and can be cost-justified based on a cost-benefit analysis.
D002140:California; D003362:Cost-Benefit Analysis; D005260:Female; D006470:Hemorrhage / Q000517:prevention & control; D006746:Hospital Bed Capacity, 500 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D010044:Outpatient Clinics, Hospital / Q000191:economics*; D010595:Pharmacists; D010607:Pharmacy Service, Hospital / Q000191:economics*; D011517:Prothrombin Time; D011897:Random Allocation; D012008:Recurrence; D012189:Retrospective Studies; D013923:Thromboembolism / Q000517:prevention & control; D013997:Time Factors; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
D014859:Warfarin